Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.

Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA.

Clin Cancer Res. 2009 Apr 15;15(8):2739-46. doi: 10.1158/1078-0432.CCR-08-1694. Epub 2009 Apr 7.

2.

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF.

Cancer Res. 2006 Feb 15;66(4):2328-37.

3.

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.

Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF.

J Biol Chem. 2006 Apr 14;281(15):10540-7. Epub 2006 Feb 16.

4.

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD.

Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

PMID:
16417259
5.

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC.

Bioconjug Chem. 2005 Sep-Oct;16(5):1282-90.

6.

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.

Cancer Res. 2005 Sep 15;65(18):8331-8. Erratum in: Cancer Res. 2006 Feb 15;66(4):2495.

7.

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, Yamane AK, Petroziello JM, Francisco JA, Wahl AF.

Leukemia. 2005 Sep;19(9):1648-55.

PMID:
16049514
8.

Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.

Torgov MY, Alley SC, Cerveny CG, Farquhar D, Senter PD.

Bioconjug Chem. 2005 May-Jun;16(3):717-21.

PMID:
15898742
9.

Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9.

Kline T, Torgov MY, Mendelsohn BA, Cerveny CG, Senter PD.

Mol Pharm. 2004 Jan 12;1(1):9-22.

PMID:
15832497
10.

Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.

Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG, Denny WA, Gordon KA, Gustin D, Haugen J, Kline T, Nguyen MT, Senter PD.

J Med Chem. 2005 Mar 10;48(5):1344-58.

PMID:
15743178
11.

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.

Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.

Clin Cancer Res. 2004 Dec 1;10(23):7842-51. Erratum in: Clin Cancer Res. 2005 May 15;11(10):3969.

12.

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA.

Clin Cancer Res. 2004 Oct 15;10(20):7063-70.

13.

Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.

Klussman K, Mixan BJ, Cerveny CG, Meyer DL, Senter PD, Wahl AF.

Bioconjug Chem. 2004 Jul-Aug;15(4):765-73.

PMID:
15264863
14.

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD.

Nat Biotechnol. 2003 Jul;21(7):778-84. Epub 2003 Jun 1.

PMID:
12778055
15.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF.

Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24.

16.

Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs.

Toki BE, Cerveny CG, Wahl AF, Senter PD.

J Org Chem. 2002 Mar 22;67(6):1866-72.

PMID:
11895404

Supplemental Content

Loading ...
Support Center